Singapore-based iX Biopharma announced on 6 August 2018 that it had received approval from Australia’s Therapeutic Goods Administration (TGA) for its sildenafil drug, which is delivered in an oral capsule for treating erectile dysfunction.
Australia approves first capsule-form Viagra generic
Generics/News
|
Posted 14/09/2018
0
Post your comment
iX Biopharma’s drug is a generic version of Pfizer’s blockbuster erectile dysfunction drug Viagra (sildenafil). The drug, which was previously known as XCalibur, will be marketed under the name Silcap in Australia. Unlike other Viagra generics in the market, which are delivered in tablet form, Silcap, is delivered using a novel, small capsule, giving an alternative dose form for patients who cannot swallow tablets.
iX Biopharma received approval from the TGA for Silcap on 31 July 2018 for 25 mg and 50 mg doses of sildenafil in pack sizes of 4, 8 and 12 capsules.
Silcap is iX Biopharma’s second treatment for erectile dysfunction and is the first capsule-form sildenafil generic to be approved for marketing in Australia.
Related articles
TGA approves three biosimilars but fewer generics in 2017
Generic competition for Pfizer’s sildenafil
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.
Source: iX Biopharma, TGA
Research
Japan’s drug shortage crisis: challenges and policy solutions
Saudi FDA drug approvals and GMP inspections: trend analysis
Related content
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment